Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB1 | P16118 | 3/20 | 0.57 |
| ▸ | PFKFB2 | O60825 | 2/20 | 0.53 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.53 |
| ▸ | NSD2 | O96028 | 3/20 | 0.51 |
| ▸ | AS3MT | Q9HBK9 | 3/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.44 |
| ▸ | TUBB | P07437 | 7/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858321 | 0.89 | PFKFB1 (0.59) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL5857036 | 0.86 | PFKFB1 (0.67) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL7037753 | 0.85 | PFKFB2 (0.43) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL30052735 | 0.83 | NSD2 (0.61) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL25229990 | 0.83 | NSD2 (0.61) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL5857137 | 0.80 | PFKFB1 (0.66) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL5857133 | 0.78 | PFKFB1 (0.67) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL5857216 | 0.76 | PFKFB1 (0.64) | PFKFB1PFKFB2PFKFB3NSD2AS3MT | |
| SCHEMBL6087078 | 0.75 | PFKFB2 (0.50) | PFKFB1PFKFB2PFKFB3TUBB4ATUBB | |
| SCHEMBL5857816 | 0.75 | AS3MT (0.55) | PFKFB1PFKFB2PFKFB3NSD2AS3MT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | claimed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | claimed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | claimed |
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | PFKFB1 3485/4885PFKFB2 3883/4885PFKFB3 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.